Discover CME, tools, and guideline-focused education to improve your knowledge - and patient outcomes.
Translating Research Into Practice in Breast Cancer: Emerging Data and the Expanding Role of ADCs
Sara A. Hurvitz, MD, FACP
Tiffany Traina, MD
On the Horizon: Emerging Antigen-Directed Strategies Across Disease Stage
Ticiana Leal, MD
Clinical Evidence on Emerging Antigen-Directed Strategies in ES-SCLC
The Survival Ceiling in ES-SCLC: Why Checkpoint Blockade Alone Is Not Enough
Neal Ready, MD, PhD
From Data to Decision: Patient Selection and Real-World Application
Christophe Le Tourneau, MD, PhD
Marc Oliva, MD, PhD
Building the Team: Integrating Immunotherapy Into Multidisciplinary Care
Clear Skin, Clear Path: Transforming Psoriasis Care with Durable Biologic and Oral IL-23 Innovations
Linda Stein Gold, MD
Lakshi Aldredge, MSN, ANP-BC
Najat M. Watch, PA
Precision in Practice—Bringing Targeted Therapy to mHSPC
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
Advancing Acromegaly Care: Diving Deeper Into Diagnosis, Guideline Application, and Emerging Therapies—A Fireside Chat With Expert Perspectives
Maria Fleseriu, MD, FACE
Beverly MK Biller, MD, FACP
Mark Gurnell, MD
The Evidence Base: Key Trials and Emerging Data
The Case for Change: Why Perioperative Immunotherapy Matters in LA HNSCC
Perioperative Immunotherapy in LA-HNSCC: From Evidence to Clinical Practice
From Abstract to Action in Breast Cancer: Interpreting Recent Data on Oral SERDs and Endocrine Targeting Strategies
Aditya Bardia, MD, MPH, FASCO
Erica L. Mayer, MD, MPH
Translating Evidence on TROP2-Directed ADCs Into Global Practice in Metastatic TNBC
Javier Cortes, MD, PhD
Cracking the Code: Risk Stratification Guidelines to Identify High-Risk Patients
ADT Intensification in Biochemically Recurrent Prostate Cancer: When to Act
The Next Generation of Care: New Treatment Frontiers in Immunotherapy-Resistant Advanced Squamous NSCLC
September 12, 2026 Seoul
Current Unmet Needs in First-Line Treatment of Metastatic TNBC
Redefining First-Line Therapy of Metastatic TNBC: Integrating TROP2-Directed ADCs Into Modern Treatment Strategy
Managing Adverse Events Associated With TROP2-Directed ADCs in Metastatic TNBC
Beyond Checkpoint Blockade in SCLC: Emerging Antigen Targets and Treatment Strategies Across Disease Stages
Rationale of Emerging Antigen-Directed Strategies in Frontline ES-SCLC
The Power of Timing: Therapies That Change Outcomes
Chairperson’s Perspective: Incorporating Novel Treatment Options for Schizophrenia Into Clinical Practice - Overcoming Clinical Inertia
Jose Rubio, MD
Today’s CLL/SLL Decisions, Tomorrow’s Options: Practical Strategies for the Community Clinic
September 11, 2026 Houston, Texas
The Future of mCSPC: Molecular Profiling and Biomarker-Directed Therapies
Neeraj Agarwal, MD, FASCO
Rana McKay, MD
Loading...
We're glad to see you're enjoying Prova Education… but how about a more personalized experience?
Press cancel to remain on Prova Education. Press the link below or the continue button to keep going.